RUSSIA PHARMA INNOVATOR GETS EBRD LOAN
April 1st, 2013
ONE of Russia’s few pharmaceutical companies developing original innovative and biotechnological medicines is receiving a Euro EUR5 million loan from the European Bank for Reconstruction & Development (EBRD). The Russian-owned and managed GEROPHARM-Bio, a subsidiary of OOO Geropharm, will use the five-year financing to expand and modernise its Obolensk plant, near Moscow, to help it comply with international standards. An EBRD note said its “main focus is on pharmaceuticals for neurology, ophthalmology and endocrinology…” It also makes genetically ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.